InCVAX is under clinical development by Immunophotonics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how InCVAX’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
inCVAX is under development for the treatment of solid tumors including melanoma, soft tissue sarcoma, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma, colorectal cancer, non-small cell lung cancer, pancreatic cancer and coronavirus disease 2019 (COVID-19) as vaccine adjuvant. It is a laser-guided cancer vaccine therapy that utilizes the combination of a laser treatment, followed by injection at the treated tumor site with an immunological stimulant (Protectin). The therapeutic candidate is administered by intratumor route. It was under development for the treatment of stage III and IV metastatic breast cancer.
Immunophotonics is a biotech company that designed to transform tumor ablation into hypnotherapy for cancer and develops immunotherapy-based treatments for cancer. Immunophotonics is headquartered in St. Louis, Missouri, the US.
For a complete picture of InCVAX’s drug-specific PTSR and LoA scores, buy the report here.